Initially, MRSA infections were typically acquired in a healthcare environment, however in more recent years community-acquired MRSA infections have predominated. According to GlobalData epidemiologists, there were 552,000 community-acquired hospitalized incident cases of MRSA in 2023, and 162,000 healthcare-acquired cases in the 7MM.
Featured Posts
“Today’s announcement was a worst-case scenario for Cardinal Health’s Optum renewal,” EvercoreISI analyst Elizabeth Anderson wrote in a note.
Drugmakers, including the genetic testing company 23andMe, are using novel approaches to stimulate NK cells’ intrinsic ability to recognize and kill tumor cells.
CVS Health has lost a bid to escape a proposed class action lawsuit accusing the company of discriminating against people with HIV by requiring them to receive their medications by mail.
Though a Sanofi spokesperson declined to provide details about the operations overhaul, including its timeline, scope and the number of employees that will be terminated, they said that the changes are part of Sanofi’s push to implement “a streamlined strategic sales structure.”
Roche’s subsidiary Genentech has successfully expanded the label of Alecensa to include the adjuvant treatment of anaplastic lymphoma kinase-positive, early-stage non-small cell lung cancer following resection.
Following a months-long safety review, the regulator said it is now requiring black box warnings for all commercially available CAR-T therapies to reflect the risk of secondary malignancies.
The World Health Organization is likely to issue a wider warning about contaminated Johnson and Johnson-made children’s cough syrup found in Nigeria last week, it said in an email.
Drug maker Vifor Pharma has offered to rectify its disparaging campaign against the closest rival to its blockbuster iron deficiency medicine Ferinject, EU antitrust regulators said on Friday, a move that would stave off a potential hefty fine and end an antitrust investigation.
China’s vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue.